Fin Cascade
Get Android appGet iOS app

Prices as of 9 Oct 2026 close · Not investment advice

Unichem Laboratories Limited

NSE: UNICHEMLABPharmaceuticals

Share price

₹531.10

+0.04% close of 9 Oct 2026

Market cap ₹3,718 CrP/E 30.7

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

60

out of 100 · worked out 9 Oct 2026

How the business score works

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹3,718 Cr

P/E ratio

30.7

P/B ratio

1.4

ROCE

4.1%

ROE

3.2%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹650.6052-week low ₹284.05

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 7.1% over the past year, and 6.7% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 5.0% to 9.8% over the last four years.

Whether it grew faster than its sector

It grew 6.7% a year against a sector median of 13.1% — 6.4 percentage points slower.

Room to re-rate, or risk of de-rating

At 30.7× earnings against a market that pays 24.1× across 2199 companies we can price. Its own industry sits at 79.4×, across 5 companies. It is against its own five-year median of 59.2×, the 28th percentile of its own range.

Whether growth justifies the valuation

Priced at 0.9 times its growth rate, on earnings growth of 35%.

Profit growthPrice per ₹1 profitPer 1% growth
Unichem Laboratories Limited — this one35%/yr30.7×₹0.88
Divi's Laboratories13%/yr83.1×₹6.4
Torrent Pharmaceuticals22%/yr79.4×₹3.6
Zydus Lifesciences32%/yr23.2×₹0.72
Laurus Labs Limited4%/yr100.5×₹25.1
Cipla10%/yr29.4×₹2.9

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 106 of 130 on returns, 94 of 127 on growth, 101 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 4.1% on capital, ahead of 18% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years the business itself consumed ₹334 crore of cash before any plant spend, funded mostly borrowed — borrowings rose from ₹349 crore to ₹500 crore. And the profit is not backed by cash: it reported a profit over 12 years and consumed cash from the business. Its cash comes back faster than it used to: it went from being waiting 207 days for its cash to waiting 169 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 10 checks clear · 60%

How the profit check works

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Announced 11 Aug 2026 · Consolidated · Unaudited

Revenue

₹633 Cr

Revenue vs last year

+20.0%

Revenue vs last quarter

+10.0%

Net profit

₹41 Cr

Profit vs last quarter

+277.0%

Net margin

6.6%

EPS

₹6.61

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹3,718 Cr
Prev close
₹531.10
52w High
₹687
52w Low
₹278
Enterprise value
₹3,923 Cr
Beta
0.8
Price CAGR 1y
16.0%
Price CAGR 3y
10.0%
Price CAGR 5y
16.0%
Price CAGR 10y
6.0%

Ratios

Return on assets
6.8%
PEG ratio
0.9
P/E ratio
30.7
P/B ratio
1.4
EV / EBITDA
17.1
Industry P/E
37.6
ROCE
4.1%
ROCE 5y average
1.2%
ROE
3.2%
Debt / Equity
0.2
Interest coverage
10.1
Dividend yield
0.0%
ROE 3y average
2.0%
ROE last year
3.0%

Annual P&L

Annual revenue
₹2,202 Cr
Annual profit
₹253 Cr
Operating margin
9.0%
Net profit margin
11.5%
EBITDA margin
8.6%
Sales growth 3y
17.9%
Sales growth 5y
12.3%
Profit growth 3y
35.0%
Profit growth 5y
25.0%
EPS
₹35.9
Sales growth TTM
7.0%
Profit growth TTM
-2.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹633 Cr
Profit latest quarter
₹41 Cr
YoY quarterly sales growth
20.1%
YoY quarterly profit growth
—
OPM latest quarter
11.1%

Balance Sheet

Book Value
₹388
Face Value
₹2.0
Total debt
₹500 Cr
Total cash
₹295 Cr
Borrowings
₹500 Cr
Reserves / Equity
193.1

Cash Flow

Operating cash flow
₹4 Cr
Free cash flow
₹163 Cr
FCF yield
3.5%
Net cash flow
₹200 Cr

Shareholding

Promoter holding
70.2%
FII holding
0.9%
DII holding
10.5%
Public holding
18.4%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,751.4533.24,20,2320.902,901.26.015,299.910.520.5
Divi's Lab.9,381.5083.62,49,0490.31902.065.53,080.027.822.0
Torrent Pharma.4,611.5578.61,75,4090.81566.05.84,921.054.915.2
Zydus Lifesci.1,117.5522.91,11,4760.09990.2-35.18,017.022.021.1
Laurus Labs2,010.0099.31,08,6030.10362.1125.52,026.329.117.8
Cipla1,295.7029.21,04,6760.98785.6-39.27,119.32.315.5
Dr Reddy's Labs1,179.1030.698,4170.67435.6-68.78,099.8-5.513.0
Unichem Labs.539.0031.03,7950.0041.5496.1632.620.14.1
Median415.0034.02,1190.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales423416466432483507533587527579521575633
Expenses395407435406443452448503504513476527563
Material Cost275217193174184190
Change in Inventories-44-233814-7.8231
Purchases of Stock-in-Trade335140499267
Employee Cost961071009993103
Other Expenses142152142140167171
Operating Profit2893125405586842266454870
OPM %6.622.116.685.878.311116144.27118.598.2911
Other Income9679-119491497-372871116
Exceptional items (within Other Income)00-58276-120
Interest6765457578797
Depreciation29293227323231303231313130
Profit before tax2-2273-1268276258-9-112931949
Tax %13212-03749681610104215
Net Profit-1-2473-1292255853-10-122641141
EPS in Rs-0.10-3.4810-180.293.508.227.52-1.49-1.69381.555.89
Diluted EPS in Rs7.50-1.49-1.69371.556.61

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,2021,3336988151,1801,1041,2351,2701,3431,7852,1112,2022,308
Expenses1,1001,1697389421,2541,1531,1441,1981,3891,6981,8462,0132,079
Material Cost888769
Change in Inventories-20020
Purchases of Stock-in-Trade176232
Employee Cost402397
Other Expenses580601
Operating Profit101164-41-128-74-499172-4687265189229
OPM %812-6-16-6-4.5076-3.404.9013910
Other Income20151842,73591915047-0-2635260277
Exceptional items (within Other Income)0202
Interest333888561723213232
Depreciation4139445167828491113123125125123
Profit before tax77137972,548-58-485122-176-85155292350
Tax %321-120-592533-5015101114
Net Profit751081092,545-24-603433-202-94138253305
EPS in Rs8.311212362-3.38-8.554.874.70-29-13203643
Diluted EPS in Rs1936
Dividend Payout %2417251-118-478285-14000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
5%
5 years
12%
3 years
18%
TTM
7%

Compounded profit growth

10 years
-3%
5 years
25%
3 years
35%
TTM
-2%

Stock price CAGR

10 years
6%
5 years
16%
3 years
10%
1 year
16%

Return on equity

10 years
11%
5 years
0%
3 years
2%
Last year
3%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital181818141414141414141414
Reserves8499361,0452,6662,6062,5172,5432,6042,4212,4242,4372,703
Borrowings223698151200206119349314248460500
Other Liabilities264283359359323407436351444589659489
Minority Interest0
Total Liabilities1,1531,2741,5213,1903,1423,1453,1123,3193,1933,2753,5693,707
Fixed Assets4164034915788108708849901,2571,2521,3001,213
CWIP1232372502389233056849414712331100
Investments4114149019265503922642100
Other Assets5746207661,4731,3131,3951,2691,5711,7871,8982,2392,394
Total Assets1,1531,2741,5213,1903,1423,1453,1123,3193,1933,2753,5693,707

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity7811268-112-3282033-260-8514-73.64
Cash from Investing Activity-52-85-1321,648-286-36-6610024163-242194
Cash from Financing Activity-51-3359-881-2-62-121191-81-1061842
Net Cash Flow-25-7-4655-616-78-1543275-29-65200
Free Cash Flow4-28-79-271-519-360-254-386-1230-142164

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days586016512413512974142160131135137
Inventory Days171184397278278374518527414365418349
Days Payable114131297230182236202161193174164128
Cash Conversion Cycle116113265172231267390508382322389358
Working Capital Days8890174133165154163207207173159169
ROCE %9159128-2-221-5-064

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters707070707070707070707070
FIIs0.830.840.900.890.941.050.980.980.990.9910.90
DIIs101011121212111111111110
Public191818171717171818181818
No. of Shareholders21,58420,87721,17120,62120,37421,47221,62123,01023,57723,26723,38625,347

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +9.2% (₹486.35 → ₹531.10)Brick size ₹30.48 (fixed)Bricks 19
₹300₹400₹600₹531Jan '26Mar '26Jun '26
Price moved up one brickPrice moved down one brickLast close ₹531.10 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

205inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

50,80,180inr

2026-03-31

News

News and filings about Unichem Laboratories Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Buys from

Sells to

  • Niche Generics Limited · generic pharmaceutical products (regulated-market export arm)
  • Unichem Farmaceutica Do Brasil Ltda · generic pharmaceutical products (Brazil export arm)
  • Unichem Pharmaceuticals (USA) Inc. · generic pharmaceutical products (US export arm)

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE351A01035

Plants

  • Unichem API Plant - Kolhapur
  • Unichem API Plant - Pithampur
  • Unichem API Plant - Roha
  • Unichem Formulation Plant - Baddi
  • Unichem Formulation Plant - Ghaziabad
  • Unichem Formulation Plant - Goa

News impact

Big market events that reach Unichem Laboratories Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

1 Aug 2022unspecified₹4
22 Jul 2021unspecified₹4
20 Aug 2020unspecified₹4
18 Jul 2019unspecified₹4
19 Jul 2018unspecified₹5
13 Jul 2017unspecified₹3
17 Mar 2016interim₹2
2 Jul 2015unspecified₹2

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
9 Jul 2026POLUNIN EMERGING MARKETS SMALL CAP FUND LLCBUY6,00,901₹646.44
11 Jun 2026NK SECURITIES RESEARCH PRIVATE LIMITEDSELL10,63,012₹486.94
11 Jun 2026NK SECURITIES RESEARCH PRIVATE LIMITEDBUY10,63,012₹486.70
11 Jun 2026JUNOMONETA FINSOL PRIVATE LIMITEDSELL9,23,655₹488.31
11 Jun 2026JUNOMONETA FINSOL PRIVATE LIMITEDBUY9,16,676₹487.89
11 Jun 2026MICROCURVES TRADING PRIVATE LIMITEDBUY8,64,382₹489.27
11 Jun 2026MICROCURVES TRADING PRIVATE LIMITEDSELL8,64,382₹489.48
11 Jun 2026IRAGE BROKING SERVICES LLPSELL7,58,636₹487.66
11 Jun 2026IRAGE BROKING SERVICES LLPBUY7,09,993₹485.58
11 Jun 2026ELIXIR WEALTH MANAGEMENT PRIVATE LIMITEDBUY6,15,503₹488.36

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.